A livestream event at 1 p.m. ET will discuss the development and impact of precision cancer medicines over the past two decades, with a focus on new approaches. Featured speakers include experts from the American Association for Cancer Research, Sarah Cannon Research Institute, and Winship Cancer Institute of Emory University. The event will be moderated by STAT’s senior biotech writer, Adam Feuerstein. The panel will explore topics such as antibody drug conjugates and tyrosine kinase inhibitors. This discussion aims to provide insight into what has been effective in precision cancer medicines and what new developments are on the horizon.
Source link
STAT Viritual Event: Cancer’s Breakthrough Engine
